https://mindmedicinelaw.com/briefing/epa-proposes-snurs-affecting-psychedelic-chemical-supply-chains-20261102-55802The Psychedelic Journalen2026-11-02T15:06:21.972703+00:00EPA Proposes SNURs Affecting Psychedelic Chemical Supply Chainsepa snur, tsca regulation, psychedelic research chemicals, chemical supply chain, regulatory compliance, premanufacture notice, significant new use, federal register, drug development delayshttps://mindmedicinelaw.com/briefing/psilocybin-s-hidden-order-in-brain-activity-implications-for-research-and-policy-20261101-55846The Psychedelic Journalen2026-11-02T15:06:39.331214+00:00Psilocybin’s 'Hidden Order' in Brain Activity: Implications for Research and Policypsilocybin, hidden order, brain activity, neuroimaging, biomarkers, clinical trial design, regulatory policy, psychedelic research, consciousnesshttps://mindmedicinelaw.com/briefing/rapid-antidepressant-effects-of-psychedelics-clinical-trial-signals-and-policy-i-20261101-55763The Psychedelic Journalen2026-11-01T22:04:56.982336+00:00Rapid Antidepressant Effects of Psychedelics: Clinical Trial Signals and Policy Implicationspsychedelics, depression, rapid antidepressant, clinical trials, regulatory policy, FDA, mechanism of action, mental health, treatment-resistant depression, risk assessmenthttps://mindmedicinelaw.com/briefing/psilocybin-in-psychiatry-clinical-and-public-health-policy-outlook-20261101-55555The Psychedelic Journalen2026-11-01T15:06:55.368838+00:00Psilocybin in Psychiatry: Clinical and Public Health Policy Outlookpsilocybin, psychiatry, public health, clinical trials, policy, regulation, safety, access equity, mental health, oregon psilocybin programhttps://mindmedicinelaw.com/briefing/psilocybin-s-molecular-links-to-depression-and-schizophrenia-pathways-20261101-55573The Psychedelic Journalen2026-11-01T15:05:50.369398+00:00Psilocybin’s Molecular Links to Depression and Schizophrenia Pathwayspsilocybin, depression, schizophrenia, molecular pathways, biomarkers, clinical trial design, precision medicine, psychedelic research, bdnf, policy implicationshttps://mindmedicinelaw.com/briefing/psilocybin-s-anti-inflammatory-effects-in-parkinson-s-implications-for-veteran-a-20261030-55762The Psychedelic Journalen2026-11-01T22:04:45.828031+00:00Psilocybin’s Anti-Inflammatory Effects in Parkinson’s: Implications for Veteran Access and Policypsilocybin, parkinson's disease, anti-inflammatory effects, veteran health policy, clinical trial design, neurodegenerative disorders, fda psychedelic guidance, biomarkers, public health impacthttps://mindmedicinelaw.com/briefing/psilocybin-alters-decision-making-under-uncertainty-insights-from-elife-study-20261030-55491The Psychedelic Journalen2026-11-01T15:07:23.383244+00:00Psilocybin Alters Decision-Making Under Uncertainty: Insights from eLife Studypsilocybin, decision-making, uncertainty, cortical processing, mechanism of action, clinical trial design, policy implications, risk assessment, psychedelic researchhttps://mindmedicinelaw.com/briefing/chiral-capillary-electrophoresis-sensitivity-advances-for-psychedelic-drug-analy-20261030-55507The Psychedelic Journalen2026-11-01T15:07:08.687615+00:00Chiral Capillary Electrophoresis: Sensitivity Advances for Psychedelic Drug Analysischiral capillary electrophoresis, psychedelic drug analysis, enantiomer detection, pharmaceutical quality control, regulatory compliance, clinical trial methods, mass spectrometry detection, enantiomeric purity, analytical chemistry advances, psychedelic manufacturinghttps://mindmedicinelaw.com/briefing/helus-pharma-s-psychedelic-adjunctive-progresses-in-u-s-phase-3-trials-20261030-55525The Psychedelic Journalen2026-11-01T15:06:44.035088+00:00Helus Pharma's Psychedelic Adjunctive Progresses in U.S. Phase 3 Trialshelus pharma, psychedelic adjunctive, phase 3 clinical trial, psych congress 2026, fda regulatory pathway, psychiatric treatment, drug-drug interactions, psychedelic medicine, clinical integrationhttps://mindmedicinelaw.com/briefing/mechanistic-uncertainty-in-psychiatric-drugs-implications-for-psychedelic-resear-20261030-55487The Psychedelic Journalen2026-11-01T15:06:30.755706+00:00Mechanistic Uncertainty in Psychiatric Drugs: Implications for Psychedelic Research and Policypsychiatric drug mechanisms, psychedelic research, clinical trial design, regulatory policy, informed consent ethics, ketamine, psilocybin, mechanistic studies, FDA, placebo responsehttps://mindmedicinelaw.com/briefing/psilocybin-modulates-decision-making-and-cortical-processing-in-animal-models-20261030-55488The Psychedelic Journalen2026-11-01T15:06:17.569518+00:00Psilocybin Modulates Decision-Making and Cortical Processing in Animal Modelspsilocybin, decision-making, reinforcement learning, cortical processing, animal model, preclinical research, clinical trial design, psychedelic therapy, neural encodinghttps://mindmedicinelaw.com/briefing/psilocybin-modulates-learning-under-uncertainty-in-rodent-study-20261030-55495The Psychedelic Journalen2026-11-01T15:06:04.335237+00:00Psilocybin Modulates Learning Under Uncertainty in Rodent Studypsilocybin, rodent study, reinforcement learning, cortical processing, uncertainty, preclinical research, neural encoding, clinical trial design, meta-learning, psychedelic mechanismshttps://mindmedicinelaw.com/briefing/music-selection-practices-in-psychedelic-therapy-new-survey-insights-20261029-55164The Psychedelic Journalen2026-10-31T22:06:50.651779+00:00Music Selection Practices in Psychedelic Therapy: New Survey Insightspsychedelic-assisted therapy, music selection, playlist integration, clinical protocols, survey research, post-session listening, patient outcomes, therapy best practices, session music, clinical trialshttps://mindmedicinelaw.com/briefing/cultural-adaptation-of-trauma-therapies-for-indigenous-peoples-in-north-america-20261029-55199The Psychedelic Journalen2026-10-31T22:06:37.295022+00:00Cultural Adaptation of Trauma Therapies for Indigenous Peoples in North Americacultural adaptation, indigenous trauma, psychedelic-assisted therapy, north america, wise practices, clinical guidelines, community collaboration, trauma interventions, public health, regulatory policyhttps://mindmedicinelaw.com/briefing/establishing-interventional-psychiatry-clinics-new-guidance-for-psychedelic-ther-20261029-55267The Psychedelic Journalen2026-10-31T22:06:24.724496+00:00Establishing Interventional Psychiatry Clinics: New Guidance for Psychedelic Therapiesinterventional psychiatry, psychedelic-assisted therapy, clinic development, regulatory compliance, staffing models, safety protocols, policy framework, clinical integration, ketamine clinics, future of psychiatryhttps://mindmedicinelaw.com/briefing/intranasal-mebufotenin-trial-for-depression-clinical-and-policy-implications-20261026-55594The Psychedelic Journalen2026-11-01T15:05:35.534521+00:00Intranasal Mebufotenin Trial for Depression: Clinical and Policy Implicationsmebufotenin, intranasal administration, treatment-resistant depression, psychedelic clinical trials, regulatory implications, novel psychedelics, public health policy, trial design, safety and efficacyhttps://mindmedicinelaw.com/briefing/peer-reviewed-evidence-lsd-microdosing-and-cognitive-enhancement-20261020-55427The Psychedelic Journalen2026-10-31T22:06:11.378158+00:00Peer-Reviewed Evidence: LSD Microdosing and Cognitive Enhancementlsd microdosing, cognitive enhancement, psychedelic research, clinical trials, public health policy, neuroplasticity, regulatory implications, safety profile, schedule i substanceshttps://mindmedicinelaw.com/briefing/ketamine-extension-vs-buprenorphine-maintenance-clinical-outcomes-compared-20261019-55853The Psychedelic Journalen2026-11-02T15:07:19.756399+00:00Ketamine Extension vs. Buprenorphine Maintenance: Clinical Outcomes Comparedketamine extension, buprenorphine maintenance, substance use disorder, opioid use disorder, clinical trial 2026, policy implications, treatment retention, comparative effectiveness, psychedelic protocols, regulatory pathwayshttps://mindmedicinelaw.com/briefing/buprenorphine-after-ketamine-for-suicidal-ideation-clinical-trial-insights-us-20-20261019-55839The Psychedelic Journalen2026-11-02T15:06:57.410945+00:00Buprenorphine After Ketamine for Suicidal Ideation: Clinical Trial Insights (US, 2026)buprenorphine, ketamine, suicidal ideation, clinical trial, psychedelic research, durability of effect, adjunctive therapy, fda regulatory guidance, opioid modulation